NXT-Dx

Gentbrugge, Belgium Founded: 2011 • Age: 15 yrs Acquired By Diagenode
Epigenetics services are offered to life science researchers.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About NXT-Dx

NXT-Dx is a company based in Gentbrugge (Belgium) founded in 2011 by Maarten Braspenning was acquired by Diagenode in August 2018. NXT-Dx operates in a competitive market with competitors including Depixus, Genomics, Seven Bridges Genomics, Hexagon Bio and BC Platforms, among others.

  • Headquarter Gentbrugge, Belgium
  • Founders Maarten Braspenning
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Diagenode

    (Aug 16, 2018)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of NXT-Dx

Investors in NXT-Dx

NXT-Dx has secured backing from 1 investor. Prominent investors backing the company include Diagenode.

All
Investor Description Founded Year Domain Location
Reagents and kits for epigenetics sequencing solutions are developed.
Founded Year Domain Location

Investments & Acquisitions by NXT-Dx

Investments

Financial Statements - NXT-Dx

Nxt-Dx Comparisons

+
Add Comparison
Available on Premium

Competitors of NXT-Dx

NXT-Dx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Depixus, Genomics, Seven Bridges Genomics, Hexagon Bio and BC Platforms, among others.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Single-molecule genetic and epigenetic sequencing solutions are provided.
domain founded_year HQ Location
Genomic risk assessment and prevention platform is provided.
domain founded_year HQ Location
Cloud-based platform to analyze, store, and act on genomic data.
domain founded_year HQ Location
Bioinformatics tools are provided for analyzing microbial genomic sequencing data.
domain founded_year HQ Location
Platforms for genomic data analysis and management are provided.
domain founded_year HQ Location
Gene-editing platform and anti-aging therapy for dogs are developed.

Latest news on Nxt-Dx

Frequently Asked Questions about NXT-Dx

NXT-Dx was founded in 2011.

NXT-Dx is headquartered in Gentbrugge, Belgium. It is registered at Gentbrugge, East Flanders, Belgium.

NXT-Dx was founded in 2011 and is based in Gentbrugge, Belgium. Services in epigenetics are provided to the life science community, including Infinium Methylation EPIC array, MBD-sequencing, MeDIP-seq, Reduced Representation Bisulfite Sequencing, and bisulfite sequencing variants for targeted, genome-wide, or whole-genome analysis. Additional offerings encompass genomics, transcriptomics, metagenomics, and bioinformatics support. Operations focus on advancing epigenetic and related genomic studies.

NXT-Dx's top competitors include Novogene Corporation, Depixus and Ingenuity Systems.

NXT-Dx has 1 investor. Key investors include Diagenode.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available